Newroom
SUL-151 as treatment for smoke-induced COPD
Sulfateq is happy to announce that a new scientific manuscript detailing the efficacy of SUL-151 to mitigate the development of Chronic Obstructive Pulmonary Disease (COPD), was recently published in the International Journal of Molecular Sciences....
SULFATEQ and GEN sign term sheet to develop a therapy for Alzheimer’s Disease
Groningen, The Netherlands & Ankara, Turkey - Sulfateq BV, an early stage biotech company developing a group of small molecules that maintain mitochondrial health, and GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), a leading...
SNN Valorisation grant for Sulfateq B.V.
We are proud to announce that Sulfateq B.V. received a Samenwerkingsverband Noord-Nederland (SNN) Valorisation grant for the development of SUL-138 as Acute Kidney Injury (AKI) prophylaxis. This grant helps us to continue the development that was...
New Paper about SUL-109
There is a new manuscript available which describes the positive effect of our SUL-109 compound which is commercially available as our ROKEPIE preservation solution. This article was written by Fatima Aerts from the Hacettepe University in Ankara...
Winterslaap voor de mens
In de zomer keihard doorgaan, en zodra het koud wordt, even de boel de boel laten. Rust. Voor velen aanlokkelijk, maar het lijkt nog toekomstmuziek. Professor Rob Henning (Rijksuniversiteit Groningen) scientific board van Sulfateq, denkt dat het in...
HypoThermosol and ROKEPIE compared
We are happy to share a new article about our product ROKEPIE which can be used to preserve cells and tissues during transport and storage. A direct comparison of HypoThermosol® and ROKEPIE was recently published in PlosONE. Freitas Robero from the...